Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Restructuring watch

Restructuring watch

Date Company Staff cuts Cash Years cash pre-cut Cash date 1H07 oper loss
7/18/07 pSivida (ASX:PSD; PSDV) >30% A$27.1 (A) 0.48 6/30/07 A$55.6 (A)(B)
Discontinues undisclosed early stage research; and transitions to a drug delivery company from a nano-biomaterials company
7/20/07 Nabi (NABI) 5% to 575 $103.9 3.29 6/30/07 $15.8
Headcount reduction in connection with a reorganization to support the new Nabi Pharmaceuticals business unit;

Read the full 678 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers